Document Detail

In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry.
MedLine Citation:
PMID:  25097196     Owner:  NLM     Status:  Publisher    
BACKGROUND: Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice.
METHODS AND RESULTS: We studied 47 040 patients with myocardial infarction treated with percutaneous coronary intervention, who received either clopidogrel or prasugrel within 24 hours of admission at 361 US hospitals from July 2009 to June 2011 using the merged Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines and CathPCI Registry database. Hierarchical logistic regression modeling was used to determine factors independently associated with in-hospital ADPri switching. Among 40 531 patients treated initially in-hospital with clopidogrel, 2125 (5.2%) were discharged on prasugrel; this frequency steadily increased from 0% to 7% during the study period. Among 6509 patients treated initially in-hospital with prasugrel, 751 (11.5%) were discharged on clopidogrel. The frequency of this switch increased from 6% to 18% during the first 2 quarters of the study period and decreased to 9% by the end. Switching clopidogrel to prasugrel was associated with high-risk angiographic characteristics (thrombotic, long, and bifurcating lesions), reinfarction in-hospital, and private health insurance coverage. Older age, previous cerebrovascular event, in-hospital coronary artery bypass grafting, in-hospital bleeding, and warfarin use at discharge were associated with switching prasugrel to clopidogrel.
CONCLUSIONS: Clopidogrel and prasugrel are not uncommonly switched in-hospital in patients with myocardial infarction undergoing percutaneous coronary intervention. In contemporary US practice, in addition to risk for bleeding and recurrent ischemic events, medical drug coverage is a major determinant of ADPri selection.
Akshay Bagai; Yongfei Wang; Tracy Y Wang; Jeptha P Curtis; Hitinder S Gurm; Binita Shah; Asim N Cheema; Eric D Peterson; Jorge F Saucedo; Christopher B Granger; Matthew T Roe; Deepak L Bhatt; Robert L McNamara; Karen P Alexander
Related Documents :
23860666 - Qtc-prolongation in posterior circulation stroke.
11209146 - Coronary magnetic resonance angiography.
24660996 - Effect of increased severity of mitral regurgitation and preprocedural right ventricula...
24429806 - On or off pump coronary bypass? insight from matched and principal component analyses o...
10454476 - Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and ...
855796 - Definition of cardiac structures using computerized tomography in isolated arrested and...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-5
Journal Detail:
Title:  Circulation. Cardiovascular interventions     Volume:  -     ISSN:  1941-7632     ISO Abbreviation:  Circ Cardiovasc Interv     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101499602     Medline TA:  Circ Cardiovasc Interv     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2014 American Heart Association, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Th22 cells are expanded in multiple sclerosis and are resistant to IFN-?
Next Document:  Association of Glycemic Control With Mortality in Patients With Diabetes Mellitus Undergoing Percuta...